Context Stereotactic ablative body radiotherapy (SABR) is an emerging treatment modality
for primary and metastatic renal cell carcinoma (RCC). Objective To review and summarise …

Oligometastatic renal cell carcinoma (OM-RCC) refers to patients who have limited (typically
up to 5) metastatic lesions. Although management principles may overlap, OM-RCC is …

Background Evidence-based guidelines for the management of systemic therapy–naïve
oligometastatic renal cell carcinoma (RCC) are lacking. Objective To evaluate the potential …

Cytoreductive nephrectomy became accepted as standard of care for selected patients with
metastatic renal cell carcinoma (mRCC) because of improved survival observed in patients …

Simple Summary Stereotactic ablative radiation therapy (SAbR) is a safe and effective local
therapy for renal cell cancer (RCC) with emerging and evolving indications. In this review we …

Context Emerging evidence supports the use of stereotactic body radiation therapy (SBRT)
as metastatic-directed therapy (MDT) for oligometastatic genitourinary cancers; however, the …

Background Metastatic renal cell carcinoma (mRCC) is a heterogenous disease with poor 5-
year overall survival (OS) at 14%. Patients with mRCC to endocrine organs historically have …

Context Although the management of metastatic renal cell carcinoma (mRCC) has been
revolutionized by the advent of new systemic agents, still few patients experience a long …

Introduction The aim of this systematic review and meta-analysis was to review evidence
and pool outcomes to assess the effectiveness of stereotactic ablative radiotherapy (SABR) …

Introduction Systemic and local therapies for patients with metastatic renal cell carcinoma
(mRCC) are often challenging despite the evolution of multimodal cancer therapies in the …